Celera Corporation

Celera Corporation is a United States biotechnology company established in 1998 by PE Corporation, later renamed Applera. It was created to generate, analyze, and commercialize genomic information and became one of the most prominent private-sector participants in the race to sequence the human genome. The company initially operated from Rockville, Maryland, before relocating its headquarters to Alameda, California. Celera's early identity was closely associated with J. Craig Venter, who became its first president after leading genomic research at The Institute for Genomic Research. At TIGR, Venter and Hamilton Smith had helped produce the first complete genome sequence of a free-living organism, the bacterium Haemophilus influenzae. Celera built on that experience by using high-throughput sequencing, computational analysis, and a whole-genome shotgun strategy. Instead of assembling the genome only through a long, staged mapping process, the company generated and computationally assembled large numbers of randomly fragmented DNA sequences. The company’s most consequential project was its sequencing of the human genome. Celera’s effort ran in parallel with the publicly funded Human Genome Project and became a highly visible commercial and scientific competitor to it. The competition encouraged the public project to accelerate its timetable. Celera stated that it could produce a human genome sequence with substantially less funding than the public effort, although its work benefited from existing sequence data that was openly available through GenBank and from technological and scientific advances developed across the wider genomics community. Celera’s business model depended not only on sequencing but also on the commercial value of genomic databases, analytical tools, and access to biological information. Its initial approach to data access prompted criticism from researchers who argued that restricting parts of a genome sequence for commercial exploitation could slow scientific progress. The company later made its sequence data available for non-commercial research under access conditions, including limits on the volume of data that could be downloaded at one time. This debate helped make Celera an important case study in the tension between open scientific resources and proprietary biotechnology information. Celera also sequenced or contributed to sequencing projects involving organisms such as the fruit fly, mosquito, mouse, and human. Over time, the company’s strategic emphasis moved away from being primarily a genome-sequencing challenger and toward diagnostic and healthcare-related applications. In 2008, Celera was separated from Applera as an independent company. Quest Diagnostics acquired Celera in 2011, after which Celera became part of Quest’s diagnostics-oriented business structure. The Celera name remains associated with genomic sequencing, bioinformatics, human-genome competition, and the commercialization of large-scale biological data.

Celera Corporation was created in May 1998 by PE Corporation, a life-sciences company that was later renamed Applera. Its original purpose was to turn large-scale DNA sequencing and genomic analysis into a commercial business. The company was first headquartered in Rockville, Maryland, and later moved to Alameda, California. J. Craig Venter became its first president. Before joining Celera, Venter had been a leading figure at The Institute for Genomic Research, where he and Hamilton Smith participated in the first successful sequencing of the complete genome of a free-living organism, Haemophilus influenzae. Celera entered the genomics industry at a moment when sequencing technology, computing power, and public biological databases were developing rapidly. Its central technical approach was whole-genome shotgun sequencing. DNA was broken into many fragments, sequenced in parallel, and reconstructed computationally by identifying overlaps among the resulting reads. This approach was designed to reduce the time and cost associated with sequencing large genomes and gave Celera a distinctive position against the more methodical mapping and sequencing strategy used by the publicly funded Human Genome Project. The human-genome project made Celera internationally prominent. The company claimed that it could sequence the human genome using approximately $300 million in private funding, compared with roughly $3 billion associated with the public effort. The comparison was not entirely equivalent: Celera benefited from publicly available sequence information, including data distributed through GenBank, and entered the project after substantial work had already been completed elsewhere. Nevertheless, its computational and sequencing strategy contributed to competitive pressure on the Human Genome Project, which accelerated its schedule and moved toward completion earlier than originally projected. Celera’s human-genome work also raised a major question about the ownership and availability of biological information. Critics objected to the prospect that sections of a genome sequenced by a private company might be withheld or made available only under commercial terms. They contrasted this position with the public project’s commitment to releasing sequence data openly. Celera subsequently adjusted its policy by making sequence information available for non-commercial research, while retaining conditions such as limits on the quantity of data that could be downloaded during a given period. The dispute became part of the broader history of debates over genomic patents, scientific openness, database access, and the commercialization of publicly relevant biological knowledge. Beyond the human genome, Celera’s sequencing portfolio included the fruit fly Drosophila melanogaster, the mosquito Anopheles gambiae, and the mouse, as well as the human genome associated largely with Venter’s genetic material. These projects demonstrated the company’s interest in applying sequencing and computational assembly across species rather than treating the human genome as a single isolated achievement. Celera sought to commercialize genomic information through databases, analytical capabilities, and related technologies. The company later shifted toward diagnostics and healthcare applications as the commercial genomics market evolved. Celera operated as an Applera business unit and was associated with Applera tracking stock, alongside the larger Applied Biosystems Group. In 2008, it was spun off as an independent company. Quest Diagnostics acquired Celera in 2011, placing the business within a major diagnostics organization. Celera is therefore remembered both as a biotechnology company in its own right and as a significant stage in the development of Quest Diagnostics’ genomic and molecular-diagnostics activities. Its historical importance rests on the interaction of sequencing innovation, computational biology, private investment, public research, and the unresolved commercial and ethical questions surrounding access to genomic data.

• 2011

  Quest Diagnostics acquires Celera

  [1]Celera Corporationen.wikipedia.org

  Quest Diagnostics acquires Celera and incorporates the company into its diagnostics and healthcare-oriented operations.

• 2008

  Celera is spun off from Applera

  [1]Celera Corporationen.wikipedia.org

  Celera becomes an independent company after operating as an Applera business unit.

• 2003

  Human Genome Project reaches completion milestone

  [1]Celera Corporationen.wikipedia.org

  The public Human Genome Project completes its work earlier than its original timetable, a development associated with the acceleration prompted in part by Celera’s competitive sequencing program.

• 2000

  Draft human-genome sequence is announced

  [1]Celera Corporationen.wikipedia.org

  Celera’s private sequencing effort produces a draft human-genome sequence in parallel with the publicly funded Human Genome Project, intensifying competition and public discussion about data access.

• 1998

  Celera Corporation is established

  [1]Celera Corporationen.wikipedia.org

  PE Corporation establishes Celera as a genomics business intended to generate and commercialize large-scale genetic information. J. Craig Venter becomes its first president.

A biotechnology and genomics company positioned around high-throughput DNA sequencing, computational genome assembly, genomic information, and later diagnostic applications.

• Genomic sequencing · 2000

  Human genome sequence

  Celera’s best-known scientific output was its draft sequence of the human genome, produced through high-throughput sequencing and whole-genome shotgun assembly. The project positioned the company as a private competitor to the Human Genome Project and demonstrated the potential of combining automated sequencing with large-scale computational analysis. Celera’s work relied partly on existing public sequence resources and became central to debates about commercial access to genomic data.

• Sequencing technology · 1998

  Whole-genome shotgun sequencing

  Celera used a whole-genome shotgun strategy in which DNA was fragmented, sequenced in parallel, and assembled through computational comparison of overlapping reads. The method was intended to increase speed and reduce the cost of sequencing large genomes. It became a defining part of Celera’s identity and contributed to broader adoption of computationally intensive approaches in genomics.

• Bioinformatics

  Genomic information databases

  Celera sought to commercialize genomic information through databases and related analytical technologies. These resources were intended to support interpretation of sequence data and create a business around access to biological information rather than sequencing alone. The company’s access policies became a prominent topic in discussions about the balance between proprietary databases and open scientific research.

• Genomic sequencing

  Comparative genome sequences

  Celera sequenced or contributed to sequencing work involving several organisms, including Drosophila melanogaster, Anopheles gambiae, and the mouse. These projects extended the company’s capabilities beyond human genomics and supplied comparative material for studying genes, genomes, and biological variation across species.

• Molecular diagnostics

  Diagnostic and healthcare applications

  In its later period, Celera moved toward diagnostic and healthcare-related applications. This strategic direction reflected the company’s attempt to translate genomic expertise into products and services closer to clinical use, before its acquisition by Quest Diagnostics in 2011.

• 2011

  Sell Celera to Quest DiagnosticsM&A

  Background

  Celera’s later business direction centered increasingly on diagnostic and healthcare applications.

  Action taken

  Quest Diagnostics acquired Celera.

  Aftermath

  Celera became part of Quest Diagnostics and its genomic capabilities were placed within a larger diagnostics organization.

  Source

• 2008

  Separate Celera from AppleraOther

  Background

  Celera had operated as an Applera business unit and had been associated with Applera tracking stock.

  Action taken

  Applera spun Celera off as an independent company.

  Aftermath

  Celera continued independently until Quest Diagnostics acquired it in 2011.

  Source

• 1998

  Compete commercially with the Human Genome ProjectStrategy

  Background

  Celera was formed to make genomic sequencing and biological information a commercial enterprise while a publicly funded international project was already sequencing the human genome.

  Action taken

  The company adopted high-throughput sequencing, whole-genome shotgun assembly, computational biology, and a commercial genomic-information model.

  Aftermath

  Celera became a prominent private competitor, encouraged the public project to accelerate, and helped make the commercial and ethical status of genome data a central issue in genomics.

  • Human Genome Project — The public project accelerated its timetable and moved toward completion in the face of Celera’s competing sequencing effort.

  Source

• Modify access to Celera sequence dataStrategy

  Background

  Researchers criticized Celera’s initial restrictions on portions of its genome sequence data, arguing that commercial control could impede scientific progress.

  Action taken

  Celera made its sequence data available for non-commercial use while retaining access conditions, including limits on the amount of information that could be downloaded at one time.

  Aftermath

  The policy change reduced the contrast with the public project’s open-access approach but preserved a commercial framework around Celera’s genomic resources.

  Source

• Shift toward diagnostics and healthcareStrategy

  Background

  After its high-profile sequencing period, Celera sought applications for its genomic capabilities beyond the production of reference genome sequences.

  Action taken

  The company redirected emphasis toward diagnostics and healthcare-related activities.

  Aftermath

  This direction aligned Celera more closely with the diagnostics sector and preceded its acquisition by Quest Diagnostics.

  Source

• 2011

  Quest Diagnostics acquires Celera[1]Celera Corporationen.wikipedia.org

  M&A

  Quest Diagnostics acquired Celera, bringing the genomics company into a larger diagnostics and healthcare organization.

• 2008

  Celera becomes independent from Applera[1]Celera Corporationen.wikipedia.org

  M&A · Other

  Celera was spun off from Applera and continued as an independent company after operating as an Applera business unit.

• 2000

  Celera and the Human Genome Project announce draft human-genome results[1]Celera Corporationen.wikipedia.org

  Product launch · Other

  Celera’s shotgun-sequencing program helped produce a draft human-genome sequence and intensified the public debate over private control, access, and commercialization of genomic data.

• 1998

  Celera enters the human-genome race against the public Human Genome Project[1]Celera Corporationen.wikipedia.org

  Other

  Celera was established by PE Corporation to generate and commercialize genomic information, creating a prominent private-sector counterpart to the publicly funded Human Genome Project.

• Celera changes access policy for its genome sequence data[1]Celera Corporationen.wikipedia.org

  Regulation · Other

  After criticism of restrictions on commercially valuable sequence information, Celera made its sequence data available for non-commercial use subject to access conditions and download limits.

1. 1Celera Corporationen.wikipedia.org
2. 2Human Genome Research Institutegenome.gov